Vespireit

Phase 3Small molecule

VValenta Pharm JSC

Vespireit is one of 8 small molecule programs targeting Vertigo. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

VertigoRecruiting

VertigoPhase 3

Recruiting

Competition

Competitive Landscape

7 competitors in Vertigo

#DrugCompanyPhaseTrials

Reglan

IIstituto Clinico Humanitas

Approved

1 2

Valium

Akero Therapeutics

Approved

—3

Dimenhydrinate

SSt. Justine's Hospital

Phase 3

2 4

Vespireit

VValenta Pharm JSC

Phase 3

1 5

Zofran

Novartis

Preclinical

1 6

Betahistine

OOBEcure Ltd.

Phase 2

1 7

Trental

VValidus Pharmaceuticals

Preclinical

1 8

Benadryl

PParkedale

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Vertigo

NCT06321341

Clinical

Trials by Indication[1]

Vertigo1 trial

Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo

Recruiting·VValenta Pharm JSC·Phase 4·NCT06321341·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vespireit. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vespireit compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vespireit. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Valenta Pharm JSC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VValenta Pharm JSC

Vespireit

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Vertigo1 trial

References

Drug Info

Quick Facts

Related News